Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Alendronic acid
Drug ID BADD_D00066
Description Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label][A959].
Indications and Usage Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget's disease of bone[FDA Label][A959,A176750]. However, alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance <35mL/min[FDA Label].
Marketing Status approved
ATC Code M05BA04
DrugBank ID DB00630
KEGG ID D07119
MeSH ID D019386
PubChem ID 2088
TTD Drug ID D09KLR
NDC Product Code Not Available
UNII X1J18R4W8P
Synonyms Alendronate | 4-Amino-1-Hydroxybutylidene 1,1-Biphosphonate | Aminohydroxybutane Bisphosphonate | MK-217 | MK 217 | MK217 | Alendronate Monosodium Salt, Trihydrate | Alendronate Sodium | Fosamax
Chemical Information
Molecular Formula C4H13NO7P2
CAS Registry Number 66376-36-1
SMILES C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Delirium19.13.02.0010.000242%
Dementia17.03.01.001; 19.20.02.0010.000484%-
Dementia Alzheimer's type17.03.06.001; 19.20.03.0010.000132%-
Dental caries07.09.01.0010.002413%
Depression19.15.01.0010.005314%
Dermal cyst16.26.02.001; 23.10.02.0010.000242%-
Dermatitis23.03.04.0020.000286%-
Dermatitis allergic10.01.03.014; 23.03.04.0030.000308%-
Dermatitis contact10.01.01.003; 12.03.01.040; 23.03.04.0040.000440%-
Dermatitis exfoliative10.01.01.004; 23.03.07.0010.000044%
Dermatomyositis10.04.04.027; 15.05.01.002; 23.03.02.0010.000044%-
Diabetes mellitus05.06.01.001; 14.06.01.0010.001057%-
Diabetes mellitus inadequate control05.06.01.004; 14.06.01.0040.000220%-
Diabetic neuropathy05.07.04.003; 14.07.04.003; 17.09.04.0020.000154%-
Diabetic retinopathy05.07.01.002; 06.10.02.002; 14.07.01.002; 24.03.07.0040.000044%-
Diaphragmatic hernia07.16.01.002; 22.09.02.0010.000044%-
Diarrhoea07.02.01.001--
Diarrhoea haemorrhagic07.02.01.002; 24.07.02.0040.000044%-
Dilatation atrial02.04.02.0190.000044%-
Dilatation ventricular02.04.02.0260.000066%-
Diplopia06.02.06.002; 17.17.01.0050.000273%-
Discomfort08.01.08.003---
Disorientation17.02.05.015; 19.13.01.002---
Diverticulum07.10.01.0010.001431%-
Diverticulum intestinal07.10.01.0020.000440%-
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.0070.002333%
Dizziness postural02.11.04.008; 17.02.05.004; 24.06.02.0080.000088%-
Drooling17.02.05.0050.000110%-
Drug hypersensitivity10.01.01.0010.004764%-
Drug interaction08.06.03.001---
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 39 Pages